268 related articles for article (PubMed ID: 21184622)
1. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.
Yin OQ; Gallagher N; Fischer D; Zhao L; Zhou W; Leroy E; Golor G; Schran H
Clin Drug Investig; 2011; 31(3):169-79. PubMed ID: 21184622
[TBL] [Abstract][Full Text] [Related]
2. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
3. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Malhotra B; Alvey C; Gong J; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):257-62. PubMed ID: 21496065
[TBL] [Abstract][Full Text] [Related]
4. Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity.
Wu JC; Nafziger AN; Bertino JS; Ma JD
Drug Metab Lett; 2012 Jun; 6(2):94-101. PubMed ID: 22594566
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
[TBL] [Abstract][Full Text] [Related]
6. Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Graefe-Mody EU; Brand T; Ring A; Withopf B; Stangier J; Iovino M; Woerle HJ
Int J Clin Pharmacol Ther; 2011 May; 49(5):300-10. PubMed ID: 21543033
[TBL] [Abstract][Full Text] [Related]
7. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
[TBL] [Abstract][Full Text] [Related]
8. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.
Zhou L; Meng F; Yin O; Wang J; Wang Y; Wei Y; Hu P; Shen Z
Clin Ther; 2009 Jul; 31(7):1568-75. PubMed ID: 19695406
[TBL] [Abstract][Full Text] [Related]
9. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin.
Padhi D; Sullivan JT
Drugs R D; 2007; 8(2):79-87. PubMed ID: 17324005
[TBL] [Abstract][Full Text] [Related]
11. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.
Ma JD; Nafziger AN; Kashuba AD; Kim MJ; Gaedigk A; Rowland E; Kim JS; Bertino JS
J Clin Pharmacol; 2004 Jun; 44(6):570-6. PubMed ID: 15145963
[TBL] [Abstract][Full Text] [Related]
12. The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers.
Uno T; Sugimoto K; Sugawara K; Tateishi T
J Clin Pharm Ther; 2008 Feb; 33(1):67-73. PubMed ID: 18211619
[TBL] [Abstract][Full Text] [Related]
13. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.
Depré M; Van Hecken A; Oeyen M; De Lepeleire I; Laethem T; Rothenberg P; Petty KJ; Majumdar A; Crumley T; Panebianco D; Bergman A; de Hoon JN
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):341-6. PubMed ID: 15983826
[TBL] [Abstract][Full Text] [Related]
14. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.
Braeckman RA; Stirtan WG; Soni PN
Clin Drug Investig; 2014 Jul; 34(7):449-56. PubMed ID: 24760401
[TBL] [Abstract][Full Text] [Related]
16. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
17. Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Almeida L; Falcão A; Vaz-da-Silva M; Nunes T; Santos AT; Rocha JF; Neta C; Macedo T; Fontes-Ribeiro C; Soares-da-Silva P
Eur J Clin Pharmacol; 2008 Oct; 64(10):961-6. PubMed ID: 18679669
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
19. Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Krishna R; Stypinski D; Ali M; Garg A; Cote J; Maes A; Degroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
Br J Clin Pharmacol; 2012 Jul; 74(1):116-24. PubMed ID: 22243494
[TBL] [Abstract][Full Text] [Related]
20. Variations in prothrombin time-international normalized ratio caused by drug-drug interaction in patients receiving warfarin: A retrospective observational study.
Shiraishi C; Hirai T; Fujita S; Dohi K; Iwamoto T
Int J Clin Pharmacol Ther; 2023 Apr; 61(4):139-147. PubMed ID: 36633369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
